Evaluation of the equivalence of different intakes of Fruitflow in affecting platelet aggregation and thrombin generation capacity in a randomized, double-blinded pilot study in male subjects

Table 2 Platelet aggregation response to ADP and thrombin generation capacity at t0 and t24, for each intervention undertaken by the subject group

		Con	FF30	FF75	FF150	FF300
Platelet aggregation in response to optimal ADP (%AUC)		N = 8	N = 8	N = 10	N = 9	N = 9
	t0	72.7 ± 17.6	71.0 ± 12.2	73.6 ± 12.8	74.5 ± 14.9	82.7 ± 13.1
	t24	76.0 ± 15.7	75.7 ± 13.7	64.5 ± 16.3^*	71.2 ± 17.6^*	70.3 ± 20.4^*
	Δ% from t0	3.0 ± 5.0 ^§	− 0.7 ± 10.2 ^§	− 12.9 ± 17.7	− 12.0 ± 13.9	− 17.7 ± 15.7
Thrombin generation capacity (nmol/L)		N = 10	N = 10	N = 10	N = 10	N = 10
	t0	324 ± 53	327 ± 59	330 ± 57	333 ± 56	328 ± 59
	t24	327 ± 53	330 ± 62	303 ± 58^*	303 ± 53^*	291 ± 54^*
	Δ% from t0	0 8 ± 3.0^§	0.8 ± 3.1^§	−8.6 ± 4.1	− 9.2 ± 3.1	− 11.3 ± 2.3

Data are shown as mean ± standard deviation. Adenosine diphosphate (ADP) agonist concentrations ranged from 1 to 8 μmol/L, and data for t0 and t24 are given as % area under the aggregation curve (%AUC). No significant differences between t0 values were detected between interventions. Where t24 is different from t0, this is indicated with *, while non-equivalence to FF150 is indicated by § (P < 0.05)

ISSN: 2055-0928